keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer biomarker

keyword
https://www.readbyqxmd.com/read/29147491/augmented-expression-levels-of-lncrnas-eccebpa-and-uca1-in-gastric-cancer-tissues-and-their-clinical-significance
#1
Mojdeh Nasrollahzadeh-Khakiani, Modjtaba Emadi-Baygi, Parvaneh Nikpour
Objectives: As the second cause of cancer death, gastric cancer (GC) is one of the eminent dilemmas all over the world, therefore investigating the molecular mechanisms involved in this cancer is pivotal. Unrestricted proliferation is one of the characteristics of cancerous cells, which is due to deficiency in cell regulatory systems. Long non-coding RNAs (lncRNAs) have emerged as critical regulators of the epigenome. lncRNA extra coding CEBPA (ecCEBPA) is involved in DNA methylation...
October 2017: Iranian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29146477/a-review-of-s100-protein-family-in-lung-cancer
#2
REVIEW
Ting Wang, Xiaoying Huo, Zhaoyang Chong, Hamadhaider Khan, Rui Liu, Ting Wang
S100 protein family, representing 25 relatively small calcium binding proteins, has been reported to be involved in multiple stages of tumorigenesis and progression. These proteins are considered having potential value to be adopted as novel biomarkers in the detection and accurate prediction of many kinds of tumors, including lung cancer. As the one having the highest morbidity and mortality among all cancers, lung carcinoma is still occult for detection, especially at early stage. S100 proteins take participation in the lung neoplasia through playing intracellular and/or extracellular functions, therefore getting involved in a variety of biological processes such as differentiation, proliferation, and migration...
November 13, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29145657/the-utility-of-blood-neuroendocrine-gene-transcript-measurement-in-the-diagnosis-of-bronchopulmonary-neuroendocrine-tumours-and-as-a-tool-to-evaluate-surgical-resection-and-disease-progression
#3
Pier Luigi Filosso, Mark Kidd, Matteo Roffinella, Anna Lewczuk, Kyung-Min Chung, Agnieszka Kolasinska-Cwikla, Jaroslaw Cwikla, Anna Lowczak, Anna Doboszynska, Anna Malczewska, Maria Catalano, Valentina Zunino, Monica Boita, Emanuela Arvat, Riccardo Cristofori, Francesco Guerrera, Alberto Oliaro, Margot Tesselaar, Wieneke Buikhuisen, Beata Kos-Kudla, Mauro Papotti, Lisa Bodei, Ignat Drozdov, Irvin Modlin
OBJECTIVES: The management of bronchopulmonary neuroendocrine tumours (BPNETs) is difficult, since imaging, histology and biomarkers have a limited value in diagnosis, predicting outcome and defining therapeutic efficacy. We evaluated a NET multigene blood test (NETest) to diagnose BPNETs, assess disease status and evaluate surgical resection. METHODS: (i) Diagnostic cohort: BP carcinoids (n = 118)-typical carcinoid, n = 67 and atypical carcinoid, n = 51; other lung NEN (large-cell neuroendocrine carcinoma and small-cell lung carcinoma, n = 13); adenocarcinoma, (n = 26); squamous cell carcinoma (n = 23); controls (n = 90) and chronic obstructive pulmonary disease (n = 18)...
November 13, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29145241/the-prognostic-value-of-the-serum-neuron-specific-enolase-and-lactate-dehydrogenase-in-small-cell-lung-cancer-patients-receiving-first-line-platinum-based-chemotherapy
#4
Xiaofan Liu, Weiming Zhang, Wen Yin, Yang Xiao, Changzhi Zhou, Yi Hu, Shuang Geng
The aim of this study was to investigate the associations of serum levels of neuron-specific enolase (NSE), pro-gastrin releasing peptide (ProGRP), and lactate dehydrogenase (LDH) with clinical response and survival in small cell lung cancer (SCLC) patients receiving first-line platinum-based chemotherapy.One hundred thirty-six patients with SCLC were recruited in this study. All the patients received first-line platinum-based chemotherapy. Clinical efficacy was assessed according to Response Evaluation Criteria in Solid Tumors v1...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143497/detection-and-monitoring-of-driver-mutations-by-next-generation-sequencing-in-squamous-cell-lung-cancer-patient-and-possible-predictive-biomarker-of-third-generation-egfr-tyrosine-kinase-inhibitors
#5
Xiaoyan Shen, Jie Shen, Hang Zhang, Yuxin Cheng, Yang Yang, Jiahui Gao, Yu Zhang, Rutian Li, Baorui Liu, Lifeng Wang
Driver mutation detection and the development of targeted drugs have significantly improved survival of advanced lung adenocarcinoma patients with driver mutations. However, we still lack understanding of druggable mutations in patients with advanced squamous cell lung cancer (SQCLC). Less than 10% of SQCLC patients have EGFR gene mutations, thus we have limited knowledge of biological molecular changes with first generation EGFR-tyrosine kinase inhibitor (TKI) resistance. We report a case of an SQCLC patient treated with first-line platinum-doublet chemotherapy...
November 16, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29142786/extraordinary-clinical-benefit-to-sequential-treatment-with-targeted-therapy-and-immunotherapy-of-a-braf-v600e-and-pd-l1-positive-metastatic-lung-adenocarcinoma
#6
Shuyu D Li, Annia Martial, Alexa B Schrock, Jane J Liu
Background: The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensive Cancer Network (NCCN) for treatment options according to biomarker testing results, sequentially applying the three main modalities (chemotherapy, targeted therapy and immunotherapy) remains an ad hoc practice in clinic. In light of recent FDA approval of dabrafenib and trametinib combination for metastatic NSCLCs with BRAF V600E mutation, one question arises due to insufficient clinical data is if the targeted therapy should be used before immunotherapy in patients with both BRAF V600E and PD-L1 expression...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29141962/personalised-medicine-for-nonsmall-cell-lung-cancer
#7
Céline Mascaux, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer...
December 31, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29140138/cox-2-expression-and-effects-of-celecoxib-in-addition-to-standard-chemotherapy-in-advanced-non-small-cell-lung-cancer
#8
Miklos Gulyas, Johanna Sofia Margareta Mattsson, Andrea Lindgren, Lars Ek, Kristina Lamberg Lundström, Annelie Behndig, Erik Holmberg, Patrick Micke, Bengt Bergman
AIM: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to demonstrate a benefit of adding COX-2 inhibitors to standard chemotherapy. The aim of this study was to analyze COX-2 expression in tumor and stromal cells as predictive biomarker for COX-2 inhibition. METHODS: In a multicenter phase III trial, 316 patients with advanced NSCLC were randomized to receive celecoxib (400 mg b...
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29138851/nrp1-positive-lung-cancer-cells-possess-tumor-initiating-properties
#9
Luis E Jimenez-Hernandez, Karla Vazquez-Santillan, Rosario Castro-Oropeza, Gustavo Martinez-Ruiz, Laura Muñoz-Galindo, Carolina Gonzalez-Torres, Carlo C Cortes-Gonzalez, Georgina Victoria-Acosta, Jorge Melendez-Zajgla, Vilma Maldonado
Tumor-initiating cells possess the capacity for self-renewal and to create heterogeneous cell lineages within a tumor. Therefore, the identification and isolation of cancer stem cells is an essential step in the analysis of their biology. The aim of the present study was to determine whether the cell surface protein neuropilin 1 (NRP1) can be used as a biomarker of stem-like cells in lung cancer tumors. For this purpose, NRP1-negative (NRP1-) and NRP1-positive (NRP1+) cell subpopulations from two lung cancer cell lines were sorted by flow cytometry...
November 9, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29138842/placenta-specific-protein-1-promotes-cell-proliferation-and-invasion-in-non-small-cell-lung-cancer
#10
Li Yang, Tian-Qi Zha, Xiang He, Liang Chen, Quan Zhu, Wei-Bing Wu, Feng-Qi Nie, Qian Wang, Chong-Shuang Zang, Mei-Ling Zhang, Jing He, Wei Li, Wen Jiang, Kai-Hua Lu
Pulmonary carcinoma-associated proteins have emerged as crucial players in governing fundamental biological processes such as cell proliferation, apoptosis and metastasis in human cancers. Placenta-specific protein 1 (PLAC1) is a cancer-related protein, which is activated and upregulated in a variety of malignant tissues, including prostate cancer, gastric adenocarcinoma, colorectal, epithelial ovarian and breast cancer. However, its biological role and clinical significance in non-small cell lung cancer (NSCLC) development and progression are still unknown...
November 9, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29138807/role-of-lasp-1-a-novel-sox9-transcriptional-target-in-the-progression-of-lung-cancer
#11
Jianguang Shi, Jing Guo, Xinjian Li
Lung cancer accounts for most cancer-related deaths worldwide. However, the underlying mechanism by which it mediates the progression of lung cancer remains unclear. Expression of LASP-1 (LIM and SH3 protein 1) was evaluated in lung cancer tissues and tumor-adjacent normal tissues using immunohistochemistry and western blotting. Functional studies have shown that siRNA-mediated silencing of LASP-1 in human lung cancer cells and reduced cell proliferation, migration, and invasion. Flow cytometry and immunofluorescence staining also revealed that rate of cell apoptosis was increased after knockdown of expression of LASP-1, thereby suggesting that LASP-1 may function as an oncogene during lung cancer progression...
November 10, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29138580/s100a16-a-promising-candidate-as-a-prognostic-marker-for-platinum-based-adjuvant-chemotherapy-in-resected-lung-adenocarcinoma
#12
Ken Katono, Yuichi Sato, Makoto Kobayashi, Ryo Nagashio, Shinichiro Ryuge, Satoshi Igawa, Masaaki Ichinoe, Yoshiki Murakumo, Makoto Saegusa, Noriyuki Masuda
Purpose: Although cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying biomarkers is important for selecting subgroups of patients who may show improved survival with platinum-based adjuvant chemotherapy. S100A16 is thought to play key roles during different steps of tumor progression. The aim of this study was to evaluate the use of S100A16 expression as a prognostic marker in patients with completely resected lung adenocarcinoma receiving platinum-based adjuvant chemotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29137702/review-of-recent-developments-in-determining-volatile-organic-compounds-in-exhaled-breath-as-biomarkers-for-lung-cancer-diagnosis
#13
REVIEW
Jiemin Zhou, Zi-Ao Huang, Ujendra Kumar, David D Y Chen
Lung cancer is the most common cause of cancer deaths, its global incidence is rising, and continuing rises are predicted. The potential to diagnose lung cancers based on the determination of volatile organic compounds (VOCs) in human breath has been attracting increasing attention with the development of new techniques and methodologies. However, despite many reports of VOC profiling in lung cancer patients, little is known about how specific biomarkers relate to the biochemical pathways involved in lung cancer development, and there is still no reliable method for diagnosing lung cancer at the early stages...
December 15, 2017: Analytica Chimica Acta
https://www.readbyqxmd.com/read/29137398/prognostic-significance-of-pd-l1-expression-and-tumor-infiltrating-lymphocyte-in-surgically-resectable-non-small-cell-lung-cancer
#14
Gen Lin, Xirong Fan, Weifeng Zhu, Cheng Huang, Wu Zhuang, Haipeng Xu, Xiandong Lin, Dan Hu, Yunjian Huang, Kan Jiang, Qian Miao, Chao Li
Programmed death ligand 1 (PD-L1) expression is a predictive biomarker of the success of PD-1/PD-L1 inhibitor therapy for patients with advanced non-small cell lung cancer (NSCLC) but its role as a prognostic marker for early stage resectable NSCLC remains unclear. Here, we studied PD-L1 expression and tumor infiltrating lymphocytes (TILs) in surgically resectable NSCLC and correlate the finding with clinicopathological features and patient outcomes. Total of 170 archival samples of resectable NSCLC were probed for PD-L1 expression using the clone 22C3 pharmDx kit...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137371/peripheral-cd4-na%C3%A3-ve-memory-ratio-is-an-independent-predictor-of-survival-in-non-small-cell-lung-cancer
#15
Peng Yang, Junhong Ma, Xin Yang, Wei Li
Background: To investigate the clinical significance of naïve T cells, memory T cells, CD45RA+CD45RO+ T cells, and naïve/memory ratio in non-small cell lung cancer (NSCLC) patients. Methods: Pretreatment peripheral blood samples from 76 NSCLC patients and 28 age- and sex-matched healthy volunteers were collected and tested for immune cells by flow cytometry. We compared the expression of these immune cells between patients and healthy controls and evaluated their predictive roles for survival in NSCLC by cox proportional hazards model...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137343/prognostic-value-of-lncrnas-in-lung-carcinoma-a-meta-analysis
#16
Fan Fan, Zhengqiu Zhu, Chao Gao, Yun Liu, Baoqing Wang, Ziquan Wang, Jifeng Feng
Many different long non-coding RNAs (lncRNAs) have been reported to be abnormally expressed in lung carcinoma and may thus serve as prognostic biomarkers for this disease. We conducted this meta-analysis, which included a total of 30 studies identified via searches of PubMed, Embase, Medline, and Web of Science and included 2912 patients from China (28), Germany (1), and Japan (1), to investigate the prognostic value of different lncRNAs in lung carcinoma. The results revealed that lncRNA transcription levels were significantly associated with overall survival in lung cancer patients (HR:1...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137254/quaking-5-suppresses-aggressiveness-of-lung-cancer-cells-through-inhibiting-%C3%AE-catenin-signaling-pathway
#17
Xuexia Zhou, Xuebing Li, Cuiyun Sun, Cuijuan Shi, Dan Hua, Lin Yu, Yanjun Wen, Feng Hua, Qian Wang, Qinghua Zhou, Shizhu Yu
Quaking-5 (QKI-5) belongs to the STAR (signal transduction and activation of RNA) family of RNA binding proteins and functions as a tumor suppressor in several human malignancies. In this study, we attempt to elucidate the role of QKI-5 in the pro-metastasis processes of lung cancer (LC) cells and the underlying mechanisms. We confirmed that QKI-5 was decreased in human LC tissues and cell lines, especially in high-metastatic cells. Moreover, QKI expression was positively correlated with LC patients' survival...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137182/current-and-prospective-protein-biomarkers-of-lung-cancer
#18
REVIEW
Tatiana N Zamay, Galina S Zamay, Olga S Kolovskaya, Ruslan A Zukov, Marina M Petrova, Ana Gargaun, Maxim V Berezovski, Anna S Kichkailo
Lung cancer is a malignant lung tumor with various histological variants that arise from different cell types, such as bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. The clinical course and treatment efficacy of lung cancer depends on the histological variant of the tumor. Therefore, accurate identification of the histological type of cancer and respective protein biomarkers is crucial for adequate therapy. Due to the great diversity in the molecular-biological features of lung cancer histological types, detection is impossible without knowledge of the nature and origin of malignant cells, which release certain protein biomarkers into the bloodstream...
November 13, 2017: Cancers
https://www.readbyqxmd.com/read/29136801/a-sensitive-label-free-electrochemical-immunosensor-for-detection-of-cytokeratin-19-fragment-antigen-21-1-based-on-3d-graphene-with-gold-nanopaticle-modified-electrode
#19
Yan Zeng, Jing Bao, Yanan Zhao, Danqun Huo, Mei Chen, Mei Yang, Huanbao Fa, Changjun Hou
Previous studies have confirmed that cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) serves as a powerful biomarker in non-small cell lung cancer (NSCLC). Herein, we report for the first time a label-free electrochemical immunosensor for sensitive and selective detection of tumor marker CYFRA21-1. In this work, three-dimensional graphene @ gold nanoparticles (3D-G@Au) nanocomposite was modified on the glassy carbon electrode (GCE) surface to enhance the conductivity of immunosensor. The anti-CYFRA21-1 captured and fixed on the modified GCE through the cross-linking of chitosan (CS), glutaraldehyde (GA) and anti-CYFRA21-1...
February 1, 2018: Talanta
https://www.readbyqxmd.com/read/29134637/ercc4-regulatory-variant-predict-grade-3-or-4-toxicities-in-patients-with-advanced-non-small-cell-lung-cancer-treated-by-platinum-based-therapy
#20
Ruoxin Zhang, Ming Jia, Yuan Xu, Danwen Qian, Mengyun Wang, Meiling Zhu, Menghong Sun, Jianhua Chang, Qingyi Wei
Platinum-based chemotherapy (PBC) in combination with the 3(rd) generation drugs is the first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy is severely hampered by grade 3-4 toxicities. Nucleotide excision repair (NER) pathway is the main mechanism of removing platinum-induced DNA adducts, contributing to the toxicity and outcome of PBC. We analyzed data from 710 Chinese NSCLC patients treated with PBC and assessed the associations of 25 potentially functional single nucleotide polymorphisms (SNPs) in eight NER core genes with overall, gastrointestinal and hematologic toxicities...
November 14, 2017: International Journal of Cancer. Journal International du Cancer
keyword
keyword
10953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"